This trial will compare three methods for identifying and risk-stratifying individuals at risk of hereditary cancer, and providing post-risk stratification longitudinal care.
1 Primary · 0 Secondary · Reporting Duration: 0 to 12 months
Experimental Treatment
18000 Total Participants · 2 Treatment Groups
Primary Treatment: online cancer risk assessment · No Placebo Group · N/A
Age 25 - 75 · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: